Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure

Table 2 Association of prior exposure to TA and/or ddI with low VAT and SAT density

	Low visceral adipose tissue density		Low subcutaneous adipose tissue density
	Crude OR [95% CI]	Adjusted OR [95% CI]*	Crude OR [95% CI]	Adjusted OR [95% CI]**
Prior exposure to TA and/or ddI	2.76 [1.97; 3.87]	1.74 [1.14; 2.67]	1.61 [1.17; 2.22]	1.74 [1.18; 2.58]
Age, per 10 years	1.78 [1.53; 2.07]	1.23 [1.01; 1.50]	1.23 [1.07;1.42]	1.17 [0.98; 1.40]
Sex, male	2.21 [1.25; 3.90]	1.73 [0.84; 3.57]	0.84 [0.53; 1.31]	2.90 [1.57; 5.35]
VAT area, per 50cm² increase	2.18 [1.91; 2.49]	1.89 [1.59; 2.25]	–	–
SAT area, per 50cm² increase	–	–	1.28 [1.16; 1.42]	2.00 [1.64; 2.43]

Abbreviations: visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; thymidine nucleoside analog reverse-transcriptase inhibitors, TA; didanosine, ddI. Multivariable models were adjusted for: age, sex, origin, physical activity, BMI, smoking, VAT* (or SAT**) area, and prior exposure to TA and/or ddI

ISSN: 1471-2334